Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

51 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Capecitabine-induced hand-foot syndrome: A pharmacogenetic study beyond DPYD.
de With M, van Doorn L, Maasland DC, Mulder TAM, Oomen-de Hoop E, Mostert B, Homs MYV, El Bouazzaoui S, Mathijssen RHJ, van Schaik RHN, Bins S. de With M, et al. Biomed Pharmacother. 2023 Mar;159:114232. doi: 10.1016/j.biopha.2023.114232. Epub 2023 Jan 9. Biomed Pharmacother. 2023. PMID: 36630849 Free article.
Influence of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib: A Randomized Crossover Pharmacokinetic Study.
de Man FM, Hussaarts KGAM, de With M, Oomen-de Hoop E, de Bruijn P, van Halteren HK, van der Burg-de Graauw NCHP, Eskens FALM, van Gelder T, van Leeuwen RWF, Mathijssen RHJ. de Man FM, et al. Among authors: de bruijn p, de with m. Clin Pharmacol Ther. 2019 Jun;105(6):1456-1461. doi: 10.1002/cpt.1331. Epub 2019 Feb 10. Clin Pharmacol Ther. 2019. PMID: 30570132 Free PMC article. Clinical Trial.
The influence of single-nucleotide polymorphisms on overall survival and toxicity in cabazitaxel-treated patients with metastatic castration-resistant prostate cancer.
Belderbos BPS, de With M, Singh RK, Agema BC, El Bouazzaoui S, Oomen-de Hoop E, de Wit R, van Schaik RHN, Mathijssen RHJ, Bins S. Belderbos BPS, et al. Among authors: de wit r, de with m. Cancer Chemother Pharmacol. 2020 Mar;85(3):547-553. doi: 10.1007/s00280-019-04011-0. Epub 2020 Jan 1. Cancer Chemother Pharmacol. 2020. PMID: 31893292 Clinical Trial.
CYP3A4∗22 Genotyping in Clinical Practice: Ready for Implementation?
Mulder TAM, van Eerden RAG, de With M, Elens L, Hesselink DA, Matic M, Bins S, Mathijssen RHJ, van Schaik RHN. Mulder TAM, et al. Among authors: de with m. Front Genet. 2021 Jul 8;12:711943. doi: 10.3389/fgene.2021.711943. eCollection 2021. Front Genet. 2021. PMID: 34306041 Free PMC article. Review.
UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients.
Hulshof EC, de With M, de Man FM, Creemers GJ, Deiman BALM, Swen JJ, Houterman S, Koolen SLW, Bins S, Thijs AMJ, Laven MMJ, Hövels AM, Luelmo SAC, Houtsma D, Shulman K, McLeod HL, van Schaik RHN, Guchelaar HJ, Mathijssen RHJ, Gelderblom H, Deenen MJ. Hulshof EC, et al. Among authors: de with m, de man fm. Eur J Cancer. 2022 Feb;162:148-157. doi: 10.1016/j.ejca.2021.12.009. Epub 2022 Jan 5. Eur J Cancer. 2022. PMID: 34998046 Free article.
Dihydropyrimidine Dehydrogenase Phenotyping Using Pretreatment Uracil: A Note of Caution Based on a Large Prospective Clinical Study.
de With M, Knikman J, de Man FM, Lunenburg CATC, Henricks LM, van Kuilenburg ABP, Maring JG, van Staveren MC, de Vries N, Rosing H, Beijnen JH, Pluim D, Modak A, Imholz ALT, van Schaik RHN, Schellens JHM, Gelderblom H, Cats A, Guchelaar HJ, Mathijssen RHJ, Swen JJ, Meulendijks D. de With M, et al. Among authors: de vries n, de man fm. Clin Pharmacol Ther. 2022 Jul;112(1):62-68. doi: 10.1002/cpt.2608. Epub 2022 May 4. Clin Pharmacol Ther. 2022. PMID: 35397172 Free PMC article.
Clinical implications of germline variations for treatment outcome and drug resistance for small molecule kinase inhibitors in patients with non-small cell lung cancer.
Heersche N, Veerman GDM, de With M, Bins S, Assaraf YG, Dingemans AC, van Schaik RHN, Mathijssen RHJ, Jansman FGA. Heersche N, et al. Among authors: de with m. Drug Resist Updat. 2022 May;62:100832. doi: 10.1016/j.drup.2022.100832. Epub 2022 Apr 5. Drug Resist Updat. 2022. PMID: 35427871 Free article. Review.
Response to letter entitled re: UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients: Is it time for everyone treated with irinotecan to be tested for UGT1A1 gene polymorphism?
Hulshof EC, de With M, Creemers GJ, Guchelaar HJ, Mathijssen RH, Gelderblom H, Deenen MJ. Hulshof EC, et al. Among authors: de with m. Eur J Cancer. 2022 Sep;172:231-233. doi: 10.1016/j.ejca.2022.05.045. Epub 2022 Jul 3. Eur J Cancer. 2022. PMID: 35793611 No abstract available.
51 results